Intravenous Iron Drugs Market Expansion Is Reshaping Competitive Dynamics Across The Industry
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Intravenous Iron Drugs Market Expansion From $4.21 Billion In 2026 To $6.33 Billion In 2030
The intravenous iron drugs sector has seen swift expansion in recent times. Valued at $3.81 billion in 2025, it is projected to reach $4.22 billion by 2026, reflecting a compound annual growth rate (CAGR) of 10.8%. This historical growth has been driven by factors such as the widespread occurrence of iron deficiency anemia, the constraints of oral iron absorption, hospital protocols for managing anemia, rising utilization in dialysis facilities, and the therapeutic efficacy of IV iron treatments.
The intravenous iron drugs market is anticipated to experience substantial expansion over the coming years, with projections indicating a rise to $6.34 billion by 2030, fueled by a compound annual growth rate (CAGR) of 10.7%. This forecasted growth is driven by factors such as the escalating prevalence of chronic conditions, an expanding population undergoing dialysis, a higher incidence of anemia associated with cancer, a growing demand for swift hemoglobin level correction, and the broadening reach of outpatient infusion services. Key trends shaping this period include the growing application of these drugs for managing iron deficiency anemia, an increasing preference for them among patients with chronic kidney disease, a shift away from oral iron supplements toward intravenous alternatives, the introduction of more single-dose iron formulations, and their enhanced use within oncology and gastroenterology fields.
Download A Free Sample Report For Comprehensive Market Insights:
#Intravenous Iron Drugs Market Growth Factors: Which Forces Are Supporting Market Expansion?
The rising prevalence of chronic kidney disease (CKD) is anticipated to drive the expansion of the intravenous iron drugs market in the coming years. Chronic kidney disease (CKD) is characterized by the progressive decline of kidney function over time, impairing the kidneys’ capacity to adequately remove waste and surplus fluids from the bloodstream. This increase in CKD incidence is largely attributed to the growing rates of diabetes and hypertension, which gradually cause kidney impairment. Intravenous iron medications are used to restore iron levels in CKD patients, correct anemia, and boost hemoglobin levels, thereby improving oxygen delivery and decreasing the reliance on erythropoiesis-stimulating agents. For example, in July 2025, a report from Hamadan University of Medical Sciences, an institution based in Iran, indicated that the global count of newly diagnosed chronic kidney disease cases is expected to reach 25.06 million by 2030. Consequently, the escalating incidence of chronic kidney disease (CKD) is fostering growth in the intravenous iron drugs market.
Intravenous Iron Drugs Market Segment Analysis: What Are The Major Market Categories?
The intravenous iron drugs market covered in this report is segmented –
1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types
2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran
2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex
3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose
4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate
Intravenous Iron Drugs Market Industry Trends: What Changes Are Reshaping Demand?
Key players in the intravenous iron drugs market are concentrating on the creation of cutting-edge treatments, such as intravenous (IV) iron replacement therapy, with the goal of boosting effectiveness, safety, and patient results. This approach involves delivering iron straight into the circulation via an IV infusion, serving as a remedy for iron deficiency and anemia, particularly for individuals who cannot handle or sufficiently absorb oral iron supplements. As an example, Daiichi Sankyo Company Limited, a pharmaceutical entity from Japan focused on pioneering drug development and healthcare services, revealed in June 2023 that the U.S. Food and Drug Administration (FDA) had given the green light to Injectafer (ferric carboxymaltose injection) for managing iron deficiency in adult heart failure patients classified as New York Heart Association class II/III, aiming to boost exercise tolerance. Injectafer stands as a frequently employed intravenous iron treatment, recognized for its swift ability to restore iron levels in patients who either cannot endure or fail to respond effectively to oral iron supplements.
Intravenous Iron Drugs Market Leading Companies Driving Competitive Growth
Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd
Access The Complete Intravenous Iron Drugs Market Report:
Intravenous Iron Drugs Market Geographic Distribution And Regional Opportunities
North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
